NFKBIA deletions and glioblastoma new product development

Today on Pharma Strategy Blog, Sally Church provides further insight into glioblastoma multiforme (GBM), the most common and deadly form of brain cancer.

Recent research has highlighted the role that encoding nuclear factor of κ-light polypeptide gene enhancer in B-cells inhibitor-α (NFKBIA) has on tumors and patient survival.

Sally analyzes the significance of this for those in the pharma/biotech industry looking to bring new products to market.

, , , , , , , , , , , ,

error: Content is protected !!